The substance.
The evidence.
The risks.

What is ibogaine?

Ibogaine is a psychoactive alkaloid found in Tabernanthe iboga, a shrub native to Central Africa. The iboga plant has a long history of use in some Central African spiritual traditions, including Bwiti. Those traditions are distinct from contemporary clinical use of isolated ibogaine.

Ibogaine acts on several systems in the brain. The body also converts it into noribogaine, an active metabolite that lasts longer. Its effects can include an intense dream-like experience, altered perception, nausea, and difficulty with balance and coordination.

It has been studied for possible effects on withdrawal symptoms and cravings, particularly in opioid dependence. A psychoactive experience, or a short-term reduction in symptoms, is not the same as sustained recovery.

Interest is growing.
Certainty is still limited.

Small studies and observational reports have described reductions in withdrawal symptoms, cravings, or substance use after ibogaine. These findings warrant research, but they do not establish that ibogaine is safe or effective for a particular person.

Personal accounts can be meaningful, but they cannot show how often treatment helps, who is most likely to benefit, or how it compares with established care. Studies may also under-represent people who experienced harm or did not return for follow-up.

Risks deserve the same attention as potential benefits.

Deaths and serious complications have been reported in connection with ibogaine. Risk depends on more than the substance alone: health conditions, other drugs, and the care environment all matter.

Assessment may include an ECG, blood tests, a medication review, and a physical and mental health evaluation. No single test or “normal” result guarantees safety. Appropriate monitoring, emergency capability, and follow-up are essential considerations.

The New Zealand context.

In Aotearoa New Zealand, ibogaine is classified as a prescription medicine. That classification is not, by itself, evidence of an approved treatment indication, proven effectiveness, or the safety of a particular provider.

Medicine classification, product approval, and individual clinical suitability are separate questions. Check current information with Medsafe and a qualified New Zealand healthcare professional rather than relying on a provider's marketing.

Your GP or an addiction service can help you consider established options, including opioid substitution treatment where appropriate, psychological support, and ongoing recovery care. Exploring ibogaine does not mean you need to stop existing treatment.

Common questions, answered carefully.

Go beyond the headline.

Use independent sources to check claims. When reading a study, look for its size, comparison group, follow-up period, and reporting of adverse events—not just its conclusion.